Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.

@article{Dziadzio2005CirculatingLO,
  title={Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.},
  author={Magdalena Dziadzio and Robert E. Smith and David J. Abraham and Carol Mary Black and Christopher P. Denton},
  journal={Rheumatology},
  year={2005},
  volume={44 12},
  pages={1518-24}
}
OBJECTIVES To determine the relationship between clinical features and circulating levels of active transforming growth factor (TGF) beta1 in the major subsets of systemic sclerosis (SSc). METHODS In a cross-sectional study cases of diffuse cutaneous SSc (dose) (n = 27) or limited cutaneous SSc (dose) (n = 20) were compared with healthy controls (n = 22). Active and total TGFbeta1 was measured in serum and plasma by a high-sensitivity enzyme-linked immunosorbent assay. RESULTS There were no… CONTINUE READING
22 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Antifibrotic therapy in scleroderma: extracellularly activated fibroblasts? Curr Rheumatol Rep 2004;6:164–70

  • J. Varga
  • 2004
1 Excerpt

Low TGF 1 serum levels are a risk factor for atherosclerotic disease in ESRD patients

  • S Stefoni, G Cianciolo, G Donati
  • Kidney Int 2002;61:324–35
  • 2002
2 Excerpts

Transforming growth factor  induces fibroblast fibrillin1 matrix

  • Z Isogai, RN Ono, S Ushiro
  • Arthritis Rheum
  • 2002

Similar Papers

Loading similar papers…